A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Phase 1

Completed

• Conditions: Bladder Neoplasms; Carcinoma, Transitional Cell

• Registration Number: NCT00001381
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.

Detailed Description

Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.

Study Timeline

• Study Start: 1994-03
• Study First Submitted: 1999-11-03
• Status Verified: 2000-01
• Study Completion: 2000-12
• Study First Submitted QC: 2002-12-09
• Study First Posted: 2002-12-10
• Last Update Submitted: 2008-03-03
• Last Update Posted: 2008-03-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

National Cancer Institute (NCI); 🇺🇸 Bethesda, Maryland, United States